Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the progression-free survival (PFS) rate
Six 28-day cycles from start of therapy
No
Andrew Beelen, MD
Study Director
Myrexis Inc.
United States: Food and Drug Administration
MPC-6827-019
NCT00892931
April 2009
September 2011
Name | Location |
---|---|
Stanford University | Stanford, California 94305 |
Cedars-Sinai Medical Center | Los Angeles, California 90048 |
Columbia University | New York, New York 10032-3784 |
Northwestern University | Chicago, Illinois 60611 |
Barrow Neurological Institute | Phoenix, Arizona 85013 |
Lahey Clinic | Burlington, Massachusetts 01805 |
Tufts Medical Center | Boston, Massachusetts 02111 |
University of Massachusettes | Worcester, Massachusetts 01655 |
Darthmouth -Hitchcock Medical Center | Lebanon, New Hampshire 03756 |
SCCA/University of Washington | Seattle, Washington 981209 |